Bipartisan Right To Try Act Would Compel DEA To Allow Psychedelics And Cannabis For Certain Patients

Congressional Reps. Earl Blumenauer (D-OR) and Nancy Mace (R-SC) filed a bill to allow terminally-ill patients to access Schedule I drugs that have been tested in clinical trials, such as cannabis and certain psychedelics under the federal Right to Try (RTT) laws.

The new HR1825 aims to “expand access to life-changing treatments by including in the federal Right to Try Act Schedule I substances that have completed Phase 1 clinical studies,” stated Blumenauer, referring to psilocybin and MDMA as the two which have shown “tremendous care potential” in both Phase 1 and 2 clinical trials.

Blumenauer, who mentioned the ongoing state-level reform movement, added that “federal restrictions have obstructed access to end-of-life care for too long.”

Federal restrictions as imposed by the DEA, which after numerous requests, still denies end-of-life patients “their freedom to elect their preferred treatments” including the possibility of using these substances in a therapeutic manner.

See also: New Psychedelic Medicine PAC Will Lobby For Advancing Research In Congress

The bill would amend the existing statute with detailed language on the cases in which it applies.

Co-sponsored by Reps. Andy Biggs (R-CA), Madeleine Dean (D-PA) and Lou Correa (D-CA), a similar 2022 measure led by Blumenauer and Mace had its Senate companion bill filed by Cory Booker (D-NJ) and Rand Paul (R-KY).

See also: Psychedelics Move Forward In Congress: Sens. Booker And Paul File 'Breakthrough Therapies Act'

Benzinga’s PCC

Benzinga’s Psychedelics Capital Conference is almost here! 

April 13th at the Fontainebleau Miami Beach Hotel will be THE place to set up deals, raise money, meet investors and key partners and learn from the industry’s greatest and most knowledgeable people.

Get your tickets now!

Photo: Benzinga edit with photo by Cburnett on Wikimedia Commons and Octavio Hoyos on Shutterstock.